A practical reference on modified GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-30 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
In 1913, Leonard Rowntree and John Jacob Abel of Johns Hopkins Hospital developed the first dialysis system which they successfully tested in animals. A Dutch doctor, Willem Johan Kolff, constructed the first working dialyzer in 1943 during the Nazi occupation of the Netherlands. Due to the scarcity of available resources, Kolff had to improvise and build the initial machine using sausage casings, beverage cans, a washing machine and various other items that were available at the time. Over the following two years (1944–1945), Kolff used his machine to treat 16 patients with acute kidney failure, but the results were unsuccessful. Then, in 1945, a 67-year-old comatose woman regained consciousness following 11 hours of hemodialysis with the dialyzer and lived for another seven years before dying from an unrelated condition. She was the first-ever patient successfully treated with dialysis. Gordon Murray of the University of Toronto independently developed a dialysis machine in 1945. Unlike Kolff's rotating drum, Murray's machine used fixed flat plates, more like modern designs. Like Kolff, Murray's initial success was in patients with acute renal failure. Nils Alwall of Lund University in Sweden modified a similar construction to the Kolff dialysis machine by enclosing it inside a stainless steel canister. This allowed the removal of fluids, by applying a negative pressure to the outside canister, thus making it the first truly practical device for hemodialysis. Alwall treated his first patient in acute kidney failure on 3 September 1946.
The Huk movement was mainly spread in the central provinces of Nueva Ecija, Pampanga, Tarlac, Bulacan, and in Nueva Vizcaya, Pangasinan, Laguna, Bataan, and Quezon. An important movement in the campaign against the Huks was the deployment of hunter-killer counter guerrilla special units. The "Nenita" unit (1946–1949) was the first of such special forces whose main mission was to eliminate the Huks. The Nenita force was commanded by Major Napoleon Valeriano. The Nenita terror tactics which were not only committed against dissidents but also towards law-abiding people sometimes helped the Huks gain supporters as a consequence. In July 1950, Major Valeriano assumed command of the elite 7th Battalion Combat Team (BCT) in Bulacan. The 7th BCT would develop a reputation toward employing a more comprehensive, more unconventional counterinsurgency strategy and reduced the random brutality against the civilian population.
The situation with SECIS in eukarya and archaea is less clear as of 2006, as the SECIS element instead occurs in the untranslated regions of the mRNA. The eukaryote homolog of SelB (EEFSEC) instead has a C-terminal domain that binds to SECISBP2 (SBP2), which carries out the actual binding of SECIS RNA. Other SECIS RNA binding proteins also exist, notably including 60S ribosomal protein L30. The archaeal homolog of SelB does not seem to have any special extension, so how it interacts with the SECIS is even less clear. The final question is how the ribosome is able to know the UGA is supposed to be coding for Sec instead of the stop codon. This question is again relatively easy to answer in bacteria, but in eukarya and archaea it presumably has some dependency on the recognition of SECIS.
Sources: en.wikipedia.org
Serena Michelle Best , is a British academic, and the Professor of Materials Science at the University of Cambridge. Best has a BSc from the University of Surrey, and a PhD from the University of London. She was elected Fellow of the Royal Academy of Engineering (FREng) in 2012. In the 2017 Birthday Honours, Best was made a CBE, "For services to Biomaterials Engineering." Best was President of the Institute of Materials, Minerals and Mining from 2019 to 2020.
== Palaeoecology == Sinosauropteryx, as a Yixian Formation dinosaur, is a member of the Jehol Biota, the assemblage of organisms found in the Yixian Formation and overlying Jiufotang Formation. The Yixian Formation is composed largely of volcanic rocks such as andesite and basalt. Between the volcanic layers are several beds of sedimentary rocks representing deposition in a lake. The freshwater lake strata of the Yixian Formation have preserved a wide variety of plants, invertebrates, and vertebrates. Gymnosperm forests were extensive, with a few early flowering plants as well. Ostracods and insects were diverse, and bivalves and gastropods were abundant. Mammals and birds are also well known from the formation. The setting was subject to periodic mortality events including volcanic eruptions, wildfires, and noxious gases erupting from the lakes. The climate has been interpreted as temperate, with distinct wet and dry seasons. The yearly temperature during this time period averaged about 10 °C (50 °F), indicating a temperate climate with unusually cold winters for the generally warm Mesozoic era, possibly due to northern China's high latitude during this time.
=== Physiological roles in organs and tissues === FcRn is expressed on antigen-presenting leukocytes such as dendritic cells and is also expressed in neutrophils to help clear opsonized bacteria. In the kidneys, FcRn is expressed on epithelial cells called podocytes to prevent IgG and albumin from clogging the glomerular filtration barrier. Current studies are investigating FcRn in the liver because there are relatively low concentrations of both IgG and albumin in liver bile despite high concentrations in the blood. Studies have also shown that FcRn-mediated transcytosis is involved with the trafficking of the HIV-1 virus across genital tract epithelium.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.